Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDuke Capital Regulatory News (DUKE)

Share Price Information for Duke Capital (DUKE)

Share Price is delayed by 15 minutes
Get Live Data
26.75    0.00 (0.00%)
Bid:
26.50
Ask:
27.00
Spread: 0.50 (1.887%)
Market Cap: £134.69m
DUKE Live PriceLast checked at - London Stock Exchange

Intraday Duke Capital Share Chart

Trading and Operational Update

31 Mar 2025 07:00

RNS Number : 7681C
Duke Capital Limited
31 March 2025
 

31 March 2025

Duke Capital Limited

 

("Duke Capital", "Duke" or the "Company")

 

Trading and Operational Update

 

Duke Capital Limited (AIM: DUKE), a leading provider of hybrid capital solutions for SME business owners in Europe and North America, is pleased to provide guidance on its trading for the fourth quarter of the financial year ending 31 March 2025 ("Q4 FY25").

 

Trading Update

 

Based on current trading, Duke expects to achieve recurring cash revenue* of £6.5 million in Q4 FY25. This represents a 12% year-on-year increase on Q4 FY24 (£5.8 million) and equal to the prior quarter, Q3 FY25, which saw the Company deliver recurring cash revenue of £6.5 million.

 

Overview of quarterly revenue growth:

 

 

Recurring Cash Revenue*

Total Cash Revenue**

Q3 FY24

£6.3 million

£6.3 million

Q4 FY24

£5.8 million

£10.2 million

Q1 FY25

£6.3 million

£6.8 million

Q2 FY25

£6.4 million

£6.8 million

Q3 FY25

£6.5 million

£6.5 million

 

* Recurring cash revenue excludes exit premium receipts and cash gains from equity sales

** Total cash revenue is monthly cash distributions from Duke's partners plus exit premium receipts and cash gains from equity sales

 

 

Operational Update

 

In February, Duke completed a £1.9 million follow-on investment into BPVA (Ireland) Limited to facilitate the acquisition of Pinta Crew Limited, an Irish consultancy business specialising in helping Irish and international organisations optimise their people, processes and resources.

 

Neil Johnson, CEO of Duke Capital, said:

 

"Despite the UK's stickier inflationary pressures, we are pleased to report that we are on track to achieve a solid year-on-year increase in recurring cash revenues for Q4 FY25. This performance reflects the strength of our business model in navigating challenging market conditions, while our follow-on investment in BPVA underscores our commitment to supporting our portfolio. With a strong balance sheet, we are confident we can deliver long-term, sustainable value for shareholders."

 

***ENDS***

 

For further information, please visit https://dukecapital.com/ or contact:

 

Duke Capital Limited

Neil Johnson / Charles Cannon Brookes / Hugo Evans

 

+44 (0) 1481 231 816

Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)

Stephen Keys / Callum Davidson / Michael Johnson 

+44 (0) 207 220 0500

 

Canaccord Genuity Limited

(Joint Broker)

 

Adam James / Harry Rees

+44 (0) 207 523 8000

SEC Newgate (Financial Communications)

Robin Tozer / Alice Cho / Olivia Hart

+ +44 (0) 20 3757 6882 dukecapital@secnewgate.co.uk

 

 

About Duke Capital

 

Duke is a leading provider of hybrid capital solutions for SME business owners in Europe and North America, combining the best features of both equity and debt.

 

Since 2017, Duke has provided unique long-term financing which eliminates re-financing risk and necessity for a short-term exit by providing a unique 'corporate mortgage' while also aligning its returns to grow with the success of the business.

 

Duke is focused on generating attractive risk-adjusted returns for shareholders and has a track record of achieving this across market cycles. It's three investment pillars are capital preservation, attractive dividend yield, and to provide upside upon exits.

 

Duke is listed on the AIM market under the ticker DUKE and is headquartered in Guernsey.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTPKFBQABKDNNB
Date   Source Headline
6th Apr 20215:17 pmRNSResult of PrimaryBid Offer and Total Voting Rights
1st Apr 20217:00 amRNSResult of Placing
31st Mar 20214:32 pmRNSPrimaryBid Offer
31st Mar 20214:30 pmRNSPlacing to raise a minimum of £30 million
31st Mar 20214:30 pmRNSExit of Investment into Royalty Partner
18th Mar 20217:00 amRNSIncreased Interim Dividend & Dividend Declaration
15th Mar 20217:00 amRNSIncreased £35 Million Revolving Credit Facility
12th Mar 20217:00 amRNSHolding(s) in Company
10th Mar 20217:00 amRNSHolding(s) in Company
1st Mar 20212:05 pmRNSSecond Price Monitoring Extn
1st Mar 20212:00 pmRNSPrice Monitoring Extension
1st Mar 20217:00 amRNSFollow-on investment into existing royalty partner
19th Feb 20217:00 amRNSHolding(s) in Company
16th Feb 20217:00 amRNSNew Royalty Partner
9th Feb 20212:36 pmRNSHolding(s) in Company
4th Feb 20217:00 amRNSTrading Update
22nd Jan 202111:44 amRNSHolding(s) in Company
14th Jan 20217:00 amRNSFollow-on investment into existing Royalty Partner
11th Jan 20217:00 amRNSAppointment of Chief Investment Officer
24th Dec 20207:00 amRNSFollow-on investment into existing royalty partner
22nd Dec 20207:01 amRNSFollow-on investment into existing royalty partner
22nd Dec 20207:00 amRNSExit of Investment in Royalty Partner
9th Dec 20207:01 amRNSInterim Results
9th Dec 20207:00 amRNSReinstated Cash Dividend and Dividend Declaration
18th Nov 20207:01 amRNSInvestor Presentation
18th Nov 20207:00 amRNSNotice of Interim Results
12th Nov 20209:05 amRNSSecond Price Monitoring Extn
12th Nov 20209:00 amRNSPrice Monitoring Extension
12th Nov 20207:00 amRNSTrading Update and Reinstatement of Cash Dividend
21st Oct 20202:34 pmRNSResult of Annual General Meeting
21st Oct 20207:00 amRNSAppointment of Joint Broker
15th Oct 20205:35 pmRNSHolding(s) in Company
14th Oct 20201:00 pmRNSDirector/PDMR Dealings
2nd Oct 20203:47 pmRNSIssue of Equity for Scrip Dividend
2nd Oct 202012:39 pmRNSLTIP, Issue of Equity, Director/PDMR Holdings
1st Oct 20201:25 pmRNSScrip Dividend Reference Price
25th Sep 20207:00 amRNSPosting of Report and Accounts and Notice of AGM
17th Sep 20207:01 amRNSFinancial 2020 Final Results
17th Sep 20207:00 amRNSDividend Declaration
16th Sep 20207:00 amRNSTrading Update
14th Sep 20207:00 amRNSSuccessful Exit of Investment in Royalty Partner
10th Aug 20207:00 amRNSHolding(s) in Company
10th Aug 20207:00 amRNSFollow-on investment into existing royalty partner
6th Aug 20207:00 amRNSTrading Update and Notice of FY 2020 Results
5th Aug 20205:43 pmRNSHolding(s) in Company
27th Jul 20202:05 pmRNSSecond Price Monitoring Extn
27th Jul 20202:00 pmRNSPrice Monitoring Extension
15th Jul 20207:00 amRNSDirector/PDMR Shareholding
3rd Jul 20203:15 pmRNSIssue of Equity for Scrip Dividend
2nd Jul 20207:00 amRNSScrip Dividend Reference Price

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.